MedinCell announces the initiation of coverage of its stock by Portzamparc – BNP Paribas Group 

• Entitled “Liberating blockbusters over the long term“, the Portzamparc – BNP Paribas Group report recommends the stock as a buy with a target price of €14.4 per share. 

• This new coverage comes as the first product based on MedinCell’s long-acting injectable technology is expected to be commercialized in the U.S. in the first half of 2023 (subject to FDA approval); two other products are in Phase 3, with several others in development. 

• MedinCell was recently awarded “Prime” status by ISS ESG for its sustainability performance, placing it in the top 10% of companies in the pharmaceutical and biotech industry. 

• MedinCell is also covered by Bryan Garnier, Kepler Cheuvreux, ODDO-BHF and TP ICAP.